Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 505

1.

Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.

Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M.

J Clin Psychopharmacol. 2012 Apr;32(2):186-94. doi: 10.1097/JCP.0b013e3182490eaf.

PMID:
22367660
2.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Malm H, Klaukka T, Neuvonen PJ.

Obstet Gynecol. 2005 Dec;106(6):1289-96.

PMID:
16319254
3.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
4.

First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27.

PMID:
17187388
5.

Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.

El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H.

Arch Gen Psychiatry. 2012 Jul;69(7):706-14. doi: 10.1001/archgenpsychiatry.2011.2333.

PMID:
22393202
6.

Antidepressants in pregnancy: a systematic review.

Udechuku A, Nguyen T, Hill R, Szego K.

Aust N Z J Psychiatry. 2010 Nov;44(11):978-96. doi: 10.3109/00048674.2010.507543. Review.

PMID:
21034181
7.

Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study.

Lupattelli A, Spigset O, Koren G, Nordeng H.

J Clin Psychopharmacol. 2014 Feb;34(1):143-8. doi: 10.1097/JCP.0000000000000036.

PMID:
24135843
8.

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.

Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernández S, Botet F, Gelabert E, Subirà S, Plaza A, Valdés M, Martin-Santos R.

J Affect Disord. 2011 Dec;135(1-3):208-15. doi: 10.1016/j.jad.2011.07.022. Epub 2011 Sep 3.

PMID:
21890210
9.

SSRI antidepressants and birth defects.

[No authors listed]

Prescrire Int. 2006 Dec;15(86):222-3.

PMID:
17167929
10.

Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.

Gentile S, Bellantuono C.

J Clin Psychiatry. 2009 Mar;70(3):414-22. Epub 2009 Feb 24. Review.

PMID:
19254517
11.

Neonate characteristics after maternal use of antidepressants in late pregnancy.

Källén B.

Arch Pediatr Adolesc Med. 2004 Apr;158(4):312-6.

PMID:
15066868
12.

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.

J Clin Psychiatry. 2004 Feb;65(2):230-7.

PMID:
15003078
13.

Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.

Lund N, Pedersen LH, Henriksen TB.

Arch Pediatr Adolesc Med. 2009 Oct;163(10):949-54. doi: 10.1001/archpediatrics.2009.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1143.

PMID:
19805715
14.

[Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].

Favrelière S, Nourrisson A, Jaafari N, Pérault Pochat MC.

Encephale. 2010 Jun;36 Suppl 2:D133-8. doi: 10.1016/j.encep.2009.06.005. Epub 2009 Sep 19. Review. French.

PMID:
20513456
15.

Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study.

N Engl J Med. 2007 Jun 28;356(26):2684-92.

16.

Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.

Nezvalová-Henriksen K, Spigset O, Nordeng H.

Headache. 2010 Apr;50(4):563-75. doi: 10.1111/j.1526-4610.2010.01619.x. Epub 2010 Jan 28. Erratum in: Headache. 2012 Sep;52(8):1319-20.

PMID:
20132339
17.

Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study.

Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, Koren G, Einarson A.

J Clin Pharmacol. 2012 May;52(5):766-70. doi: 10.1177/0091270011405524. Epub 2011 Nov 10.

PMID:
22075232
18.

Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Nørgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B.

BMJ. 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012.

PMID:
22240235
19.

Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT.

Br J Clin Pharmacol. 2008 Apr;65(4):600-6. Epub 2007 Oct 22.

20.

Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome.

Malm H.

Ther Drug Monit. 2012 Dec;34(6):607-14. doi: 10.1097/FTD.0b013e31826d07ea. Review.

PMID:
23042258

Supplemental Content

Support Center